Evaluation of Intravenous Anthrax Immune Globulin for Treatment of Inhalation Anthrax
- 1 November 2013
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (11), 5684-5692
- https://doi.org/10.1128/aac.00458-13
Abstract
Bacillus anthracis toxins can be neutralized by antibodies against protective antigen (PA), a component of anthrax toxins. Anthrivig (human anthrax immunoglobulin), also known as AIGIV, derived from plasma of humans immunized with BioThrax (anthrax vaccine adsorbed), is under development for the treatment of toxemia following exposure to anthrax spores. The pharmacokinetics (PK) of AIGIV was assessed in naive animals and healthy human volunteers, and the efficacy of AIGIV was assessed in animals exposed via inhalation to aerosolized B. anthracis spores. In the clinical study, safety, tolerability, and PK were evaluated in three dose cohorts (3.5, 7.1, and 14.2 mg/kg of body weight of anti-PA IgG) with 30 volunteers per cohort. The elimination half-life of AIGIV in rabbits, nonhuman primates (NHPs), and humans following intravenous infusion was estimated to be approximately 4, 12, and 24 days, respectively, and dose proportionality was observed. In a time-based treatment study, AIGIV protected 89 to 100% of animals when administered 12 h postexposure; however, a lower survival rate of 39% was observed when animals were treated 24 h postexposure, underscoring the need for early intervention. In a separate set of studies, animals were treated on an individual basis upon detection of a clinical sign or biomarker of disease, namely, a significant increase in body temperature (SIBT) in rabbits and presence of PA in the serum of NHPs. In these trigger-based intervention studies, AIGIV induced up to 75% survival in rabbits depending on the dose and severity of toxemia at the time of treatment. In NHPs, up to 33% survival was observed in AIGIV-treated animals. (The clinical study has been registered at ClinicalTrials.gov under registration no. NCT00845650.)Keywords
This publication has 31 references indexed in Scilit:
- Effect of Anthrax Immune Globulin on Response to BioThrax (Anthrax Vaccine Adsorbed) in New Zealand White RabbitsAntimicrobial Agents and Chemotherapy, 2013
- Development of an Inhalational Bacillus anthracis Exposure Therapeutic Model in Cynomolgus MacaquesClinical and Vaccine Immunology, 2012
- Characterization of a Therapeutic Model of Inhalational Anthrax Using an Increase in Body Temperature in New Zealand White Rabbits as a Trigger for TreatmentClinical and Vaccine Immunology, 2012
- Tetanus – A Review Of Current Concepts In ManagementBenin Journal of Postgraduate Medicine, 2009
- Reduced Neutrophil Count in People of African Descent Is Due To a Regulatory Variant in the Duffy Antigen Receptor for Chemokines GenePLoS Genetics, 2009
- Interlaboratory Comparison of Results of an Anthrax Lethal Toxin Neutralization Assay for Assessment of Functional Antibodies in Multiple SpeciesClinical and Vaccine Immunology, 2008
- Pathology of Inhalational Anthrax Infection in the African Green MonkeyVeterinary Pathology, 2007
- Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United StatesEmerging Infectious Diseases, 2001
- AnthraxNew England Journal of Medicine, 1999
- THE TREATMENT OF TETANUS WITH ANTITOXINAnnals of Surgery, 1937